Clinical Concepts on Thyroid Emergencies by Giampaolo Papi et al.
REVIEW ARTICLE
published: 01 July 2014
doi: 10.3389/fendo.2014.00102
Clinical concepts on thyroid emergencies
Giampaolo Papi , Salvatore Maria Corsello and Alfredo Pontecorvi*
Department of Endocrinology, Catholic University of Rome, Rome, Italy
Edited by:
Bernadette Biondi, Federico II
University of Naples, Italy
Reviewed by:
Maria Moreno, University of Sannio,
Italy
Giovanni Vitale, Istituto Auxologico
Italiano – Universita’ Degli Studi Di
Milano, Italy
Fabio Orlandi, Presidio Ospedaliero
Gradenigo, Italy
*Correspondence:
Alfredo Pontecorvi , Department of
Endocrinology, Catholic University of
Rome, Largo A. Gemelli 1, 00168
Rome, Italy
e-mail: pontecorvi@rm.unicatt.it
Objective:Thyroid-related emergencies are caused by overt dysfunction of the gland which
are so severe that require admission to intensive care units (ICU) frequently. Nonetheless, in
the ICU setting, it is crucial to differentiate patients with non-thyroidal illness and alterations
in thyroid function tests from those with intrinsic thyroid disease.This review presents and
discusses the main etiopathogenetical and clinical aspects of hypothyroid coma (HC) and
thyrotoxic storm (TS), including therapeutic strategy flow-charts. Furthermore, a special
chapter is dedicated to the approach to massive goiter, which represents a surgical thyroid
emergency.
Data Source: We searched the electronic MEDLINE database on September 2013.
Data Selection and Data Extraction: Reviews, original articles, and case reports on
“myxedematous coma,” “HC,” “thyroid storm,” “TS,” “massive goiter,” “huge goiter,”
“prevalence,” “etiology,” “diagnosis,” “therapy,” and “prognosis” were selected.
Data Synthesis and Conclusion: Severe excess or defect of thyroid hormone is rare con-
ditions, which jeopardize the life of patients in most cases. Both HC andTS are triggered by
precipitating factors, which occur in patients with severe hypothyroidism or thyrotoxicosis,
respectively.The pillars of HC therapy are high-dose l-thyroxine and/or tri-iodothyroinine; i.v.
glucocorticoids; treatment of hydro-electrolyte imbalance (mainly, hyponatraemia); treat-
ment of hypothermia; often, endotracheal intubation and assisted mechanic ventilation
are needed. Therapy of TS is based on beta-blockers, thyrostatics, and i.v. glucocorticoids;
eventually, high-dose of iodide compounds or lithium carbonate may be of benefit. Surgery
represents the gold standard treatment in patients with euthyroid massive nodular goiter,
although new techniques – e.g., percutaneous laser ablation – are helpful in subjects at
high surgical risk or refusing operation.
Keywords: hypothyroid coma, thyrotoxic storm, hyperthyroidism, thyrotoxicosis, hypothyroidism, massive goiter
INTRODUCTION
Emergencies related to thyroid gland diseases are infrequently
observed in the clinical practice (1–3). They are caused by either
overt dysfunction (4, 5) or marked enlargement of the gland
(6) that jeopardize the life of patients, and require admission to
intensive care units (ICU) in most cases.
The present paper reviews hypothyroid coma (HC), thyrotoxic
storm (TS), and massive goiter, discussing related etiopathogen-
esis, clinical aspects, diagnostic challenges, and prognosis, and
finally presenting therapeutic strategy flow-charts.
REVIEW CRITERIA
The content of the present review is based on the previous reviews,
original articles, and case reports on thyroid emergencies. We
searched the electronic MEDLINE database on September 2013
for a combination of the following search terms: “myxedematous
coma,” “hypothyroid coma,” “thyroid storm,” “thyrotoxic storm,”
“massive goiter,” “huge goiter,” “prevalence,” “etiology,” “diagno-
sis,”“therapy,” and “prognosis.” Only papers written in the English
language were included in this review.
EMERGENCY RELATED TO THYROID HORMONE EXCESS OR
DEFICIENCY
Either excess or deficiency of thyroid hormones is caused by sev-
eral thyroid disorders. Whatever is the underlying cause, both
thyrotoxicosis and hypothyroidism deeply impact on cardiovascu-
lar and digestive systems, basal metabolism, neuro-psychological
functions, muscles, and cutis. Rarely, the excess or the defect
of thyroid hormone is so severe that jeopardize the life of
patients, who should be promptly referred to the emergency
department.
Boxes 1 and 2 summarize “classical” definitions of thyro-
toxicosis and hypothyroidism and thyroid diseases predispos-
ing to TS and HC, respectively. Really, such definitions easily
apply to patients in the ambulatory setting, but do not reflect
what commonly happens in critically ill subjects. Yet, it is cru-
cial to establish a correct diagnosis in order to differentiate
patients with non-thyroidal illness – i.e., affected by the so-called
“euthyroid sick syndrome” (Box 3) – by those truly affected by
severe thyroid disorders, as the therapeutic approach changes
profoundly.
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Box 1 Definition of thyrotoxicosis. Thyroid diseases causing thyrotoxicosis and predisposing to thyrotoxic storm (TS).
In this review, “subclinical thyrotoxicosis” was defined as a condition characterized by low-undetectable serumTSH with normal free thyroid
hormone concentrations (7). “Overt thyrotoxicosis” was defined as a condition with suppressed serum thyrotropin (TSH) and elevated free
thyroid hormone concentrations (8).
A cut-off limit of serum thyroid hormone concentrations precipitating TS cannot be established, as serum free-thyroxine (FT4) and free
tri-iodothyronine (FT3) concentrations in thyrotoxic storm (TS) patients are as high as in hyperthyroid ones without TS.
The following thyroid diseases have been described in association with TS:
Graves’ disease; iodine- and amiodarone-induced thyrotoxicosis; toxic nodular goiter; cytokine- and tyrosine-kinase inhibitors-induced
hyperthyroidism; subacute de Quervain’s thyroiditis; post-partum thyroiditis; and radiation thyroiditis.
Factitious (voluntary) intake of high-dose l-Thyroxine has been reported as a cause of TS, too.
Box 2 Definition of hypothyroidism. Thyroid diseases causing hypothyroidism and predisposing to hypothyroid coma (HC).
In this review, “subclinical hypothyroidism” was defined as a condition characterized by normal thyroid hormone levels and high serum
TSH concentrations (9–11). “Overt hypothyroidism” was defined as a condition with serumTSH concentrations exceeding the normal range
associated to low serum free thyroid hormone level (12).
Chronic (Hashimoto’s) thyroiditis and cytokine- and tyrosine-kinase inhibitors-induced hypothyroidism have been so far reported in association
with hypothyroid coma (HC).
Total thyroidectomy; neck external beam radiotherapy;131I treatment of hyperthyroidism; use of anti-thyroid drugs (methimazole, propylth-
iouracyle), sedatives, and analgesics have been also reported as a cause of HC.
HYPOTHYROID COMA
Hypothyroid (or myxedematous) coma (HC) is the result of a
very severe, as yet untreated, hypothyroidism (25). It represents an
endocrine emergency that should be handled in ICU.
In a background of thyroid hormone deficiency, HC is usu-
ally triggered by precipitating factors, as low outside tempera-
tures, systemic (mainly, pulmonary) infections, congestive heart
failure (CHF), labor, cerebrovascular events, intake of anesthet-
ics, depressants, neuroleptics, or large liquid amounts (25–31). It
manifests rarely, with a prevalence approaching 0.1% of hospital-
ized hypothyroid patients, and particularly affects female subjects
aged >60 years (32). Even if l-thyroxine replacement therapy is
quickly and appropriately given, about 15–20% of patients finally
die (1).
ETIOLOGY
Most patients referred to the hospital for HC are already fol-
lowed by the endocrinologist or the general practitioner because
of hypothyroidism consequent to autoimmune chronic thyroidi-
tis, thyroidectomy or Graves’ disease treated by radioiodine (131I).
Usually, these subjects have previously been taking l-thyroxine
substitution therapy, unless they have subsequently withdrawn it
on their own initiative. Rarely, the cause of HC is not of primary
thyroid origin, but is because of reduced TSH excretion by the
pituitary gland (e.g., hypopituitarism) (33).
Patients presenting with secondary hypothyroidism have been
previously submitted to surgery or radiotherapy because of pitu-
itary adenoma, or are affected by pituitary macroadenoma over-
whelming TSH-producing pituitary cells. Some drugs – e.g., amio-
darone and lithium – may directly cause hypothyroidism and HC
(22–24). Amiodarone is an anti-arrhythmic drug containing high
(about 37 mg) iodine amounts. Approximately 15% of patients
taking amiodarone develop hypothyroidism or thyrotoxicosis,
mainly depending on concurrent thyroid disease (e.g., autoim-
mune or nodular thyroid disease) and daily iodine intake (21).
Amiodarone might cause hypothyroidism inducing inhibition of
5′-deiodinase activity and Wolff–Chaikoff effect. Lithium is com-
monly used to treat bipolar disorders, inhibits thyroid hormone
release from the thyroid gland, and increases thyroid autoimmu-
nity if present before therapy (30, 34, 35). Severe hypothyroidism
as a result of impaired iodine uptake by thyrocytes has been
described in neoplastic patients treated with tyrosine-kinase selec-
tive inhibitors (36). Finally, the case of a Chinese patient referred
to the hospital with HC provoked by ingestion of raw bok choy
has been reported (37). It has been demonstrated that plants of the
family of Brassicaceae contain glucosinolate, a sulfur-containing
organic anions bonded to glucose that is hydrolyzed to thio-
cyanate, a compound known for its competition with iodine.
Ingestion of large amounts of Brassicaceae induces goiter and
hypothyroidism (38).
DIAGNOSIS
The diagnosis of HC is based on (1) the history of previous thyroid
disease and progressive lethargy; (2) peculiar signs and symptoms
(Table 1); (3) serum free T4 (FT4) and free T3 (FT3) concen-
trations below the normal reference range; and (4) serum TSH
concentrations far exceeding the normal reference range. With
regard to TSH values, they usually exceed 100 mIU/L in most severe
and long-lasting cases; however, in patients with hypopituitarism
(where serum TSH concentrations are typically low-normal) (5,
39) and in those with recent-onset hypothyroidism, serum TSH
concentrations may not be so high.
The diagnosis of HC is relatively simple. However, because
serum thyroid hormone and TSH measurement commonly take
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Box 3 The euthyroid sick syndrome (ESS).
Patients affected by critical illness frequently manifest alterations in serum thyroid hormone concentrations, although they do not really
suffer from thyroid disease (13). This condition is known as “euthyroid sick syndrome” (ESS), “non-thyroidal illness,” or – less commonly at
the moment – “low T3 syndrome” (14).
ESS is the direct consequence of changes in the function of hypothalamus-pituitary-thyroid axis, in thyroid hormone metabolism and even
in thyroid gland function per se, occurring in critical illness and sometimes induced by drugs (15). So far published studies have reported
alterations in deiodinase activity,TSH secretion, hormone binding to serum proteins, thyroid hormone transport into tissues, and the nuclear
thyroid hormone receptors.
Starvation and sepsis are the conditions that physician working in the intensive care units (ICU) most commonly deal with and represent
the paradigms for ESS (16). The laboratory hallmark of ESS, at least in its early phase, is low serum T3 concentration, typically associated
to TSH levels in the low-normal range, so representing a variant of secondary or tertiary hypothyroidism (17). Concurrent low serum T4
concentrations represent a prognostically unfavorable sign (18).
Decreased binding to carrier proteins may occur in ESS (19), supporting the value of free rather than total thyroid hormone measurement
in this setting (20). The use of drugs – e.g., furosemide, heparin, non-steroidal anti-inflammatory drugs, amiodarone, anti-epileptic drugs,
dopamine, dobutamine, glucocorticoids, and somatostatin – might also have a significant impact on thyroid hormone andTSH levels (21, 22).
Thus, TSH measurement alone should be avoided in the context of ICU, as in the absence of thyroid function tests it might be misleading
and induce physicians to treat patients for hyperthyroidism.
During the recovery phase from ESS, transient elevation – usually not exceeding 20 mIU/L – in serum TSH concentrations may occur (23),
resembling the recovery phase from subacute “de Quervain” thyroiditis. At this point in time, ESS should be accurately differentiated by
subclinical hypothyroidism. SerumTSH concentrations above 20 mIU/l, high anti-thyroglobulin and anti-thyroperoxidase autoantibody levels,
and/or a diffusely hypoechoic aspect of the thyroid gland on US are in favor of primary hypothyroidism, and should suggest to start levothy-
roxine substitution therapy. Conversely, studies so far conducted in the literature have demonstrated that levothyroxine substitution therapy
is not indicated in patients with ESS (24).
Table 1 | Symptoms and signs peculiar to hypothyroid coma.
Coma status
Hypothermia (frequently severe, with body temperature <33°C)
Dyspnea
Generalized edema with yellow and dry cutis
Macroglossia
Bradycardia
Weak wrists
Reduced cardiac sounds
Overweight/obesity
Constipation
Reduced reflexes
Thin and dry hairs
Focal and general seizures (rare)
hours, once arrived at the hospital, besides serum TSH, FT4, and
FT3 concentration measurement, patients should undergo further
(i.e., first level) examinations:
- Arterial hemogasanalysis, to eventually detect hypoxemia, hyper-
capnia, and respiratory acidosis.
- Labanalysis, which may reveal anemia, hyponatraemia, hypo-
glycemia, high serum creatine kinase, lactate dehydroge-
nase, transaminases, creatinine, and cholesterol concentra-
tions. Potential mechanisms underlying hyponatraemia in HC
patients are represented by increased serum anti-diuretic hor-
mone (ADH) (40) and impaired water excretion and urine
output due to reduced delivery of water to the distal nephron
(41). The atony of urinary bladder with the consequent urine
retention and the high serum creatine kinase concentrations due
to rhabdomyolysis may lead to renal failure (15, 42).
- Electrocardiography, usually demonstrating sinus bradycardia,
low voltages (related to pericardial effusion), Q–T prolongation
and flattened or inverted T waves (consequent to myocardial
ischemia).
- Echocardiography, which may disclose a pericardial effusion
associated to cardiomegaly, increased thickness of all cardiac
walls and reduced cardiac output.
- Computed tomography (CT) of the brain that is normal in most
patients with primary hypothyroidism (although long-lasting
hypothyroidism promotes atherogenesis and, then, ischemic
encephalopathy),and generally detects pituitary macroadenoma
or an empty sella in patients with secondary hypothyroidism.
TREATMENT
The pillar of HC therapy is l-thyroxine or l-thyroxine plus
liothyronine substitution therapy preferably administered intra-
venously, owing to the poor intestinal absorption related to severe
hypothyroidism (Figure 1). Because of the rarity of HC, prospec-
tive studies recruiting large series of patients and evaluating the
best therapeutic regimens are lacking in the literature. Therefore,
this topic is still controversial. The major matter of debate con-
cerns the starting dose of substitution therapy. Some authors (43)
recommend starting with high-dose (300–400 mcg/daily) of T4
i.v., but sudden cardiac death has been reported and most recent
literature does not support such a regimen. Rapid correction of
hypothyroidism may be tolerated by young otherwise fit adults,but
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i.v. LIOTHYRONINE and/or L-THYROXINE
1. Water  restriction
2. 0.9% NaCl solutions if Na+ <120 mEq/l
etiologic therapy
treatment of electrolyte imbalance
1. Assisted mechanic ventilation in patients with
respiratory acidosis
2. i.v. furosemide if pulmonary edema occur
3. Treat hypothermia (temperature <35 C)
selected cases  
BE  AWARE OF:
- Concurrent hypoadrenalism (Schmidt’s syndrome)
- Concurrent panhypopituitarism
i.v. HYDROCORTISONE
support therapy
FIGURE 1 | Flow-chart of therapeutic approach to hypothyroid coma.
these are not the usual patients presenting with HC. Other authors
(15, 44) suggest to give liothyronine 10–20 mcg i.v. as bolus ini-
tially, followed by 10 mcg every 4 h for the first 24 h and every
6 h for days 2–3, and then to start oral administration if feasible.
Alternatively, a T3 plus T4 approach might be used: an initial dose
of 250 mcg of intravenous T4 might be administered, followed by
100 mcg 24 h later and 50 mcg per day (i.v. or by mouth) after
that. Simultaneously with the first T4 bolus (day 1), a 10 mcg T3
as i.v. bolus is given followed by 10 mcg i.v. every 8–12 h until the
patients is conscious and taking maintenance T4 (15).
Beyond thyroid hormone substitution therapy, hydrocortisone
100 mg every 6 h intravenously and treatment of hydro-electrolyte
imbalance should be administered. In particular, hyponatraemia
should be first corrected through water restriction. 0.9% NaCl
solutions (slow at 12 mmol/l/24 h) should be administered to
patients with severe hyponatraemia (<120 mEq/L) only. Hyper-
tonic saline should be used cautiously to avoid osmotic demyelin-
ization syndrome (1, 15). The use of diuretics is generally suggested
after the administration of hypertonic saline in order to promote
a water diuresis (15).
Hypothermia is to be treated through passive and gradual heat-
ing (e.g., by blankets); in contrast, the active body heating is
not warranted because of the risk of vasodilatation and shock.
Endotracheal intubation and assisted mechanic ventilation with
constant monitoring of haemogasanalysis parameters are needed
in case of severe respiratory acidosis.
At the same time, treatment of precipitating factors, if any, is
needed. For instance, large spectrum antibiotics must be admin-
istered to patients with pneumonia, after samples for urine
and blood cultures have been previously collected awaiting for
laboratory report (3). Furthermore, particular attention must
be paid to concurrent diseases in the context of autoimmune
polyendocrine syndromes. In particular, hypoadrenalism due to
Schmidt’s syndrome (association of autoimmune adrenalitis and
Hashimoto’s thyroiditis) should be ruled out (45, 46). Nonetheless,
hypoadrenalism might occur as the consequence of panhypopi-
tuitarism. In any case, until results of hypothalamus–pituitary–
adrenal axis study will be available, intravenous glucocorticoids
administration is always mandatory together with l-thyroxine
therapy, to avoid the occurrence of acute adrenal insufficiency
(45). Hypoglycemia is a serious and common complication of
HC and should be recognized and treated as soon as possible by
intravenous glucose solutions.
Death is caused by respiratory and/or cardiac (arrhythmias,
acute myocardial infarction, acute pulmonary edema, and cardiac
shock) complications (47, 48). Although both right and left heart
failure may occur in HC, the former is a clue to hypothyroidism.
Reduced stroke volume should be consequent to either reduced
myocardial contractility per se or cardiac tamponade. In patients
with pulmonary edema, diuretics (particularly, i.v. furosemide)
must be added to the standard HC therapy. Torsades de pointes
ventricular tachycardia might be the result of prolonged Q–T
interval, and therefore patients should be carefully and constantly
monitored with particular regard to this life-threatening event. Use
of digoxin is not indicated in subjects with tamponade, and should
generally be very cautious in HC patients because of prolonged
half-life and decreased volume of distribution. If a treatment with
digoxin is started, serum digoxin levels should be monitored reg-
ularly and dosage should be administered very slowly increasing.
Myocardial infarction is not uncommon in subjects with HC and
can be precipitated by too high l-thyroxine doses needed to treat
HC in patient with underlying ischemic cardiomyopathy. Owing
to impaired consciousness, clinical alert related to ischemic events
is lacking in HC patients, and therefore cardiac enzymes – also in
the absence of typical electrocardiographic features of myocardial
infarction – should be routinely measured in such condition.
Importantly, HC patients are at high risk of bleeding caused by
an acquired von Willebrand syndrome and reduction in coagula-
tion factors V, VII, VIII, IX, and X (15, 49). Such a risk is reversible
with L-T4 substitution therapy (49).
THYROTOXIC STORM
Thyrotoxic storm represents the extreme consequence of a severe
thyrotoxicosis (4, 50). As HC, TS is frequently triggered by typical
precipitating factors that occur when patients are already affected
by overt (occasionally, subclinical) hyperthyroidism (51).
The main triggering factors so far reported are summarized in
Table 2.
Fortunately, TS is a rare event mostly affecting hyperthyroid
patients who have not been adequately treated or have withdrawn
thyrostatic therapy on their own initiative or have undergone
surgery (52–54). Its prevalence averages 1% of hospitalized sub-
jects with hyperthyroidism (53) and is more frequent in the female
gender, with a female to male ratio of about 3 to 1 (55). In a recent
study, an incidence of TS cases in Japan was estimated to be 0.2
persons/100,000 Japanese population/year, accounting for 0.22%
of all thyrotoxic patients and 5.4% of thyrotoxic patients admitted
to the hospital (55). In the same series, the mean age of TS patients
was 45 years, ranging 6–87 years, without differences between men
and women (55).
Prognosis is unfavorable in many cases, unless an adequate
treatment is quickly done (56). Indeed, adequate therapy reduces
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Table 2 | Known triggers of thyrotoxic storm.
Withdrawal of anti-thyroid drug therapy
Major surgery (particularly, thyroidectomy)
Iodide compounds intake or radioiodine (131I or 123I) therapy in patients
with Graves disease or autonomously functioning thyroid nodules
Trauma (mainly, in the neck area)
Systemic infections
Pregnancy/parturition
Infection
Diabetic ketoacidosis
Severe emotional stress
Cerebrovascular disease
Pulmonary thromboembolism
Intense exercise
Use of tyrosine-kinase inhibitors
Minor surgery (extraction of teeth)
TS mortality to 10% cases approximately (56, 57). Death occurs
because of multi-organ failure in about 25% of patients and
because of CHF in 1 out of 5 cases (55); respiratory fail-
ure, arrhythmia, disseminated intravascular coagulation, gastro-
intestinal tract perforation, and sepsis represent the cause of death
in the remaining cases (55).
ETIOLOGY
Why serum FT4 and FT3 concentrations in TS patients are as
high as in hyperthyroid ones without TS, is still a matter of debate.
Indeed, the clinical picture characteristic of TS is not related to thy-
roid hormone levels (55). Nonetheless, patients presenting with TS
have a larger amount of catecholamine binding sites ubiquitously
than hyperthyroid subjects who do not develop it.
In accordance with the long-standing evidence on the inter-
relations between thyroid hormone and catecholamines (58), the
most agreed etiopathogenetic hypothesis is that, in presence of
both a larger availability of adrenergic receptors and a reduction
of thyroid hormone binding to TBG (thyroid hormone binding
globulin), the leak of catecholamine provoked by an acute event
(i.e., triggering factor) finally precipitates TS.
Pregnancy and the post-partum period are both at high risk of
TS occurrence (59–61). Indeed,on the one hand, the altered coagu-
lation state peculiar to pregnancy might be worsened by thyrotox-
icosis (see Diagnosis section); on the other hand, immune system
modulation – and “re-modulation” in the post-natal phase –
may give origin to a new-onset autoimmune hyperthyroidism, or
reawaken a previously present (i.e., pre-conception) one (59–62).
Recent radioiodine treatment of severely hyperthyroid patients
(i.e., subjects manifesting marked signs and symptoms of thy-
rotoxicosis, suppressed TSH, markedly elevated free T4 and/or
free T3, and elevated radioactive iodine uptake) represents a risk
factor for the development of TS (63–67). However, it has been
Table 3 | Symptoms and signs peculiar to thyrotoxic storm.
Fever
Unreasonable anxiety, confusion, delirium up to coma state
Tachyarrhythmia (particularly, atrial fibrillation)
Tachypnea and dyspnea
Congestive heart failure up to cardiac shock
Lerman-means scratch (pleuro-pericardiac sound)
Increased systolic vs. diastolic blood pressure ratio
Hyperhidrosis and skin hyperemia
Generalized tremors
Diarrhea
Nausea
Vomit
demonstrated that it is safe to administer I-131 to patients who are
severely hyperthyroid without fear of TS, provided beta blockade
drugs are used to control the signs and symptoms (67).
Furthermore, external radiation therapy for neck neoplasm
might cause thyroid follicle rupture and, consequently, the leak-
age of large amounts of pre-formed thyroid hormones into the
systemic blood circulation, finally precipitating TS (67). The same
mechanism underlies severe thyrotoxicosis and thyrotoxic coma
seldom provoked by acute (68) or subacute (69, 70) thyroiditis. In
contrast, the etiopathogenesis of the TS occurring in patients with
partial hydatiform mole (71) can be ascribed to thyroid hyper-
function with high 24-h RAIU, following beta-HCG follicular cell
stimulation.
Anecdotal cases of accidental (72) or voluntary (73) thyroid
hormone ingestion unleashing TS have been reported. Finally,
analogously to what happens in HC, the use of tyrosine-kinase
inhibitors, particularly sorafenib (74), may trigger TS in cancer
patients.
DIAGNOSIS
Clinically, TS presents as multi-organ failure in most cases (75,
76). The organs mainly affected by thyroid hormone excess are the
heart – tachyarrhythmia ranging from sinus tachycardia to atrial
fibrillation is invariably present (77–79), the nervous system (80,
81), the gastro-intestinal tract (82, 83), and the liver (79, 84). Fever
is also a frequent event (85, 86).
History of recent traumas in the neck area should always be
searched for in patients without history of thyroid disease (87–
90). Occasionally, the clinical picture of apathetic thyrotoxicosis
occurs, in particular in older patients (91).
The diagnosis of TS is based on: (1) history of thyroid dis-
ease and eventual triggering factors; (2) typical signs and symp-
toms (Table 3); (3) serum FT4 and FT3 concentrations exceeding
the normal reference range and undetectable (<0.1 mIU/L) TSH
levels (92).
Besides altered thyroid function tests, elevation of serum biliru-
bin levels (seldom associated to jaundice) and transaminase (93),
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hyperglycemia, low total cholesterol values and electrolyte imbal-
ance (in Asian men, hypokalemia and associated periodic paraly-
sis) are frequently detected. Total serum bilirubin level concentra-
tions >3 mg/dl have been associated to high risk of death in TS
patients, independently of jaundice (55).
Nonetheless, an altered coagulation state – in particular,
antithrombin deficiency and increased levels of factor VIII – has
been observed in patients with TS (94, 95), sometimes induc-
ing disseminated intravascular coagulation (79, 96). Individuals
exceptionally presenting with hypoglycemia, associated (97) or
not (79) to lactic acidosis, have been described, as well.
The diagnostic criteria for TS were indicated in 1969 by Maz-
zaferri et al. (98) who included temperature ≥100°F (37.8°C),
marked tachycardia, accentuated signs, and symptoms of thyro-
toxicosis and evidence of dysfunction in one more of the central
nervous, cardiovascular, or gastro-intestinal systems.
Burch and Wartofsky (56) introduced a punctual score system
to identify TS patients definitely. Such score system was composed
of the following items: temperature (ranging from 37.2 to>40°C);
central nervous system effects (from mild agitation to coma,
passing through the psychotic state); gastro-intestinal-hepatic dys-
function (including diarrhea, nausea/vomiting, abdominal pain,
and unexplained jaundice); heart rate (ranging 90 to ≥140 bpm);
atrial fibrillation; heart failure (low score pedal edema – high score
pulmonary edema); and negative or positive precipitant history.
A score of 45 or more is highly suggestive of TS; a score of 25–44
supports the diagnosis; a score below 25 makes TS unlikely.
Recently, Akamizu et al. (55) have reported the diagnostic
criteria of TS based on Japanese Nationwide surveys. They uti-
lized five symptoms – i.e., central nervous system manifestations,
fever (≥38°C), tachycardia (≥130 bpm), CHF, and gastrointesti-
nal (GI)-hepatic manifestations – to define diagnostic criteria for
“definite” (TS1) or “suspected” (TS2) cases of TS. Based on the
combination of thyrotoxicosis and the above mentioned symp-
toms, they defined TS1 patients as those presenting with thyrotox-
icosis and at least three combinations of fever, tachycardia, CHF,
or GI/hepatic manifestations. Suspicion for TS (TS2 cases) should
raise when patients meet the diagnostic criteria for TS1, except
that FT3 or FT4 values are not available but data before or after
the episode suggest that they are thyrotoxic at the time of TS.
Differences in TS diagnostic criteria between Burch and Wartof-
sky (56) and Akamizu et al (55) are reported in Table 4. Actually,
the score system for TS proposed by Akamizu neither signifi-
cantly differs from, nor adds substantial advantages to, the prior
Burch–Wartofsky criteria. Nevertheless, it should be highlighted
that Japanese population enrolled in Akamizu et al.’s study is dif-
ferent from American and European populations by the genetic
point of view. One of possible examples of such a difference is that,
in their series, TS patients affected by Graves’ disease exceeded
95%, whereas in non-Asian series – particularly in those from
Europe, where areas of mild to moderate iodine insufficiency are
still present – a higher incidence of patients with toxic nodular
goiter, iodine-induced hyperthyroidism, or destructive thyroiditis
should be expected. Therefore, certain clinical manifestations, like
as jaundice, may be expressed at different degrees in Asian com-
pared to non-Asian patients; analogously, a difference in patient’s
response to treatment should be taken into account, too.
Table 4 | Differences in diagnostic criteria for thyrotoxic storm
between Burch and Wartofsky and the Japanese survey.
Criterion Burch and Akamizu et al.
Wartofsky
Thyrotoxicosis Not included Pre-requisite
Scoring system Included Not included
Fever ≥37.2° ≥38°C
Heart rate ≥90 bpm ≥130 bpm
Atrial fibrillation Included Not included
Heart failure Pedal edema to
pulmonary edema
NYHA classification class IV
or Killip classification ≥III
Serum bilirubin
concentrations
Not included >3 mg/dL
Jaundice Included Not included
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A. Propranolol
B. Propylthiouracyle (best option) or Methimazole
C. Hydrocortisone
etiologic therapy: 1st line
A. Assisted mechanic ventilation in case of hypoxemia
B. Cooled mattresses and cold poultices in case of
hyperthermia (if body temperature >40 C)
selected cases  
support therapy
A. Lugol solution or Potassium iodide or Sodium iodide
B. Lithium carbonate
C. L-Carnitine
etiologic therapy: 2nd line
A. Repolarizing electolyte solutiions
B. Paracetamol
C. Phenobarbital
D. Furosemide and ACE-inhibitors in case of cardiac
failure
FIGURE 2 | Specific and support therapy in patients with thyroid storm.
TREATMENT
The initial treatment of TS is resuscitation. Patients are at high
risk of severe hypoxemia and tissue ischemia and need oxygen
(Figure 2). Most of them need intubation and mechanic venti-
lation. Furthermore, it is mandatory to start fluid infusion and
electrolyte correction as soon as possible.
Specific TS treatment – i.e., therapy given to reduce thyroid
hormone excess in the bloodstream and its deleterious periph-
eral effects – relies on the following medications, in order of
importance (99–101):
1. Beta-blockers: propranolol 1–2 mg intravenously or 40–80 mg
per os every 8 h is the drug of choice because, on the one
hand, contrasts the increased binding of catecholamine to beta-
adrenergic receptors, on the other hand, reduces the T4 to T3
peripheral deiodination.
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2. Thyrostatics: methimazole 15–20 mg every 6 h or propylthy-
ouracyle with a loading dose of 500–1000 mg followed by
250 mg every 4 h (15, 102). The latter should be preferred
because it reduces the T4 to T3 peripheral deiodination. How-
ever, methimazole may be given intravenously in case the
patient is not able to swallow and a total parenteral nutrition
is needed. It should be mentioned that rectal administra-
tion of both methimazole and propylthyouracyle is allowed,
at a dose of 400–600 mg every 6 h and 20–40 mg every 8–6 h,
respectively.
3. Large iodine amount : Lugol solution (10 drops three times
daily) or saturated potassium iodide solution (5 drops three
times daily) per os or sodium iodide 500–1000 mg daily intra-
venously inhibits thyroid hormone leakage by the thyroid
gland. Iodine should be administered not sooner than 1 h after
anti-thyroid drug administration.
4. Glucocorticoids: hydrocortisone 100 mg intravenously every
6–8 h reduces the T4 to T3 peripheral deiodination.
5. Lithium carbonate: 300 mg every 6–8 h inhibits proteolysis of
colloid, and is administered as an alternative to inorganic iodine
to limit the release of pre-formed thyroid hormone into the
bloodstream.
Extracorporeal plasmapheresis is an additional tool for remov-
ing circulating thyroxine in patients who do not respond
quickly to conventional standard therapy (103). Besides, a sup-
port therapy including liquids (particularly, repolarizing elec-
trolyte solutions), antipyretics (e.g., paracetamol) and pheno-
barbital (which plays a sedative role and reduces serum FT4
and FT3 concentrations by increasing thyroid hormone metab-
olism) may be of benefit. Because salicylates compete with thy-
roid hormone for binding to carrier proteins and may cause
a transient increase in serum free T4 concentrations, their use
should be avoided in the treatment of TS. l-Carnitine, a nat-
urally occurring inhibitor of thyroid hormone nuclear uptake,
was able to reverse and prevent symptoms of hyperthyroidism
in a randomized, double-blind, and placebo-controlled clin-
ical trial (104), and has been effectively used in successive
thyroid storms in association with low doses of methima-
zole (105).
If CHF is present, not only liquid should be administered cau-
tiously, but large amounts of diuretics (intravenous furosemide)
are frequently required in association with specific cardiac sup-
port therapy (78). Indeed, cardiac insufficiency in TS patients
is mostly categorized as NYHA functional class IV and/or Kil-
lip class III or IV, and many patients manifest pulmonary edema
and high output-induced cardiogenic shock (55). ACE-inhibitors
in association with beta-blockers are the cornerstones of thera-
peutic strategy in TS patients with heart failure, as much as heart
rate (≥130 bpm) tachycardia occurs.
Atrial fibrillation is observed in up to 40% of TS patients (55),
in whom heparin therapy is obviously indicated; however, changes
occurring in patients with TS may lead to heparin resistance and
pro-coagulation state (94–96).
High body temperatures must be reduced by cooled mattresses
and cold poultices. Moreover, in the presence of infections, soon
after blood and urine specimens have been obtained for cultures,
large spectrum antibiotics should be promptly started waiting for
culture results.
In the TS Japanese series, factors relevant to the mortality
were presence of multi-organ failure; presence of disseminated
intravascular coagulation; and presence of shock. In the same
series, Glasgow Coma Scale and blood urea nitrogen values pre-
dicted irreversible damages (55). Thus, these conditions should be
recognized and adequately treated.
Once the patient is stable, the differential diagnosis of thy-
roid disease underlying TS should be accurately investigated, with
the aim of distinguishing thyroid hyperfunction, destructive thy-
roiditis or thyrotoxicosis factitia. Based on the patient’s history
and clinical presentation, the work-up should consider the use of
thyroid ultrasound, possibly including color-power imaging for
evaluation of gland’s volume, echogenicity, vascularity, and pres-
ence of nodular disease. Serum anti-TSH receptor autoantibody
concentrations should be measured in cases suspected, and with-
out previous history, of Graves’ disease. If destructive thyroiditis
or thyrotoxicosis factitia is suspected, serum thyroglobulin mea-
surement and, in the latter, measurement of fecal thyroid hormone
excretion should be obtained; nonetheless, in both cases Tc99m
thyroid scan should detect scanty/absent radionuclide uptake in
the thyroid bed.
COMPRESSIVE SYMPTOMS CAUSED BY HUGE GOITER AND
AGGRESSIVE THYROID TUMORS
Nowadays, patients affected by goiter – diffuse or nodular – are
rarely submitted to emergency thyroidectomy or tracheotomy due
to compressive symptoms on esophagus and/or trachea, such as
dysphagia, dysphonia, and dyspnea. Indeed, appropriate thera-
peutic strategies (e.g., surgery or radioiodine therapy) are usually
applied before massive goiter development.
The disease mainly affects female gender and the prognosis is
usually favorable, except for malignancies (106, 107).
ETIOLOGY
Thyroid disorders eventually causing emergency due to goiter
mass-effect are the following: long-lasting benign huge goiters,
for which patients previously refused surgery or radioiodine ther-
apy (6, 108–110); massive hematoma occurring within a thyroid
nodule (111, 112); primary malignancies of the thyroid gland (par-
ticularly, anaplastic carcinoma) (113); metastases to thyroid (114);
and fibrous Riedel’s thyroiditis (115).
DIAGNOSIS AND THERAPY
The diagnosis of goiter-related compressive symptoms is based on
symptoms and signs complained by patients. Imaging examina-
tions either confirm the clinical suspicion or show the surgeon
goiter’s extension toward the neighboring structures, and particu-
larly cleavage plans. The clinical picture is characterized by dyspnea
with hypoxemia and respiratory acidosis, stridor, dysphonia, dys-
phagia, and difficult or impossible extension/flexion of the neck
(6, 108–110). Rarely, superior vena cava syndrome (116, 117) or
even chylothorax (118) occur. Huge mediastinal goiter causing
precordial pain has been reported in one patient (119).
Symptoms of compression of the tracheal tree might be relieved
by the administration of a CPAP mask. This notwithstanding,
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surgery represents the gold standard treatment in patients with
massive goiter (120, 121). Ultrasound, CT and magnetic reso-
nance (MRI) of the neck represent useful diagnostic tools before
surgery (122, 123). Some ultrasound aspects (hypoechogenicity,
punctate calcifications, undefined margins, high intranodal vas-
cularity, and more tall than width lesion) are peculiar to thyroid
malignant nodules (122), and suggest the need of performing
fine needle aspiration biopsy. Indeed, a pre-surgical diagnosis of
thyroid malignancy obtained by cytological examination should
induce the surgeon to perform a total rather than a decom-
pressive only, partial thyroidectomy. On the contrary, in case of
benign goiter, surgery should be more limited (e.g., sub-total or
near-total thyroidectomy), to reduce the risk of damaging one
or both recurrent laryngeal nerves and/or causing permanent
hypoparathyroidism.
99mTc or radioiodine (123I or 131I) thyroid scan is indi-
cated to detect hot nodules and intrathoracic goiter (109, 123).
Indeed, in patients who present huge toxic multinodular goiter
and are at high surgical risk and/or refuse operation, radioio-
dine (131I) therapy should obtain good results on compressive
symptoms (109, 124). Recently, radioiodine therapy and percu-
taneous laser ablation have been proposed as helpful alternative
methods to effectively reduce goiter size in subjects affected by
euthyroid nodular goiter containing “cold” nodules on thyroid
scan (125–127).
In patients affected by Riedel’s thyroiditis, a rare form of
fibrosing thyroiditis, when therapy with glucocorticoids fails to
improve the clinical picture and symptoms are so severe that
surgery is mandatory, isthmus resection is usually enough to
relieve compressive complaints (115).
Urgent tracheotomy is performed in cases of anaplastic thy-
roid carcinoma (113), poorly differentiated thyroid carcinoma or
thyroid metastases (114), when the neoplasm is not confined to
the neck or invades surrounding tissues so widely that cleavage
plans are undetectable, but palliative surgery is mandatory due to
acute respiratory insufficiency. Patients with massive goiter have
an extremely high risk for local complications when submitted to
tracheotomy: therefore, if any, this procedure should be performed
in an operating room by skilled surgeons.
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APPENDIX
KEY POINTS
• Severe excess or defect of thyroid hormone represent rare
conditions jeopardizing the life of patients in most cases.
• It is crucial to differentiate patients with non-thyroidal illness –
i.e., affected by the so-called “euthyroid sick syndrome” – by
those truly affected by severe thyroid disorders,as the therapeutic
approach changes profoundly.
• Both HC and TS are triggered by peculiar precipitating fac-
tors, which occur in patients with severe hypothyroidism or
thyrotoxicosis, respectively.
• The pillars of HC’s therapy are high-dose l-thyroxine and/or
tri-iodothyroinine; i.v. glucocorticoids; treatment of hydro-
electrolyte imbalance (mainly, hyponatraemia); treatment of
hypothermia; often, endotracheal intubation and assisted
mechanic ventilation are needed.
• Therapy of thyroid storm is based on beta-blockers, thyrosta-
tics, and i.v. glucocorticoids; eventually, high-dose of iodide
compounds or lithium carbonate may be of benefit.
• Surgery represents the gold standard treatment in patients with
euthyroid massive nodular goiter, although new techniques –
e.g., percutaneous laser ablation – are helpful in subjects at high
surgical risk or refusing operation.
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